Neil Dahiya

AVPN and Bayer Foundation Launch US$ 5 Million ‘Climate x Health: Lighthouse for Asia’ Fund to Safeguard Local Health

AVPN, recognized as Asia’s leading social investment network, has introduced the ‘Climate x Health: Lighthouse for Asia’ initiative with support from the Bayer Foundation. The US$ 5 million fund was unveiled at the Singapore Pavilion during COP29 in Baku, Azerbaijan. […]

AVPN and Bayer Foundation Launch US$ 5 Million ‘Climate x Health: Lighthouse for Asia’ Fund to Safeguard Local Health Read More »

Endo Broadens Recall of Clonazepam Orally Disintegrating Tablets Due to Potential Carton Strength Mislabeling

**Endo’s Expansion on Clonazepam Tablet Recall Over Potential Packaging Mislabeling** Endo, Inc., a multifaceted pharmaceutical corporation, has communicated that its subsidiary, Endo USA, Inc., will be broadening the initial voluntary recall of clonazepam orally disintegrating tablets, USP (C-IV). This decision

Endo Broadens Recall of Clonazepam Orally Disintegrating Tablets Due to Potential Carton Strength Mislabeling Read More »

Telangana Achieves Status as Leading Global Life Sciences Hub with Investments Surpassing Rs. 36,000 Crore, Generating 51,000 Jobs

The Telangana government has reported remarkable strides in the life sciences sector, successfully securing over Rs. 36,000 crore in investments from more than 140 initiatives in the past year. These investments are poised to create 51,000 direct employment opportunities and

Telangana Achieves Status as Leading Global Life Sciences Hub with Investments Surpassing Rs. 36,000 Crore, Generating 51,000 Jobs Read More »

Linerixibat Shows Promising Phase III Results for PBC-Related Cholestatic Pruritus in GSK’s GLISTEN Trial

GSK plc has unveiled encouraging top-line results from the GLISTEN trial, an expansive Phase III clinical study investigating the efficacy of linerixibat, a novel targeted inhibitor of the ileal bile acid transporter (IBAT), in treating adults suffering from cholestatic pruritus

Linerixibat Shows Promising Phase III Results for PBC-Related Cholestatic Pruritus in GSK’s GLISTEN Trial Read More »